Eiger Biopharmaceuticals Inc. (EIGR) Shares Sold by Eventide Asset Management LLC

Eventide Asset Management LLC reduced its holdings in shares of Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR) by 49.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 63,000 shares of the biotechnology company’s stock after selling 62,000 shares during the quarter. Eventide Asset Management LLC owned 0.60% of Eiger Biopharmaceuticals worth $621,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. DRW Securities LLC bought a new position in Eiger Biopharmaceuticals in the first quarter valued at about $158,000. Knott David M lifted its holdings in Eiger Biopharmaceuticals by 181.2% in the first quarter. Knott David M now owns 61,857 shares of the biotechnology company’s stock valued at $609,000 after acquiring an additional 39,857 shares during the period. BlackRock Inc. lifted its holdings in Eiger Biopharmaceuticals by 181.0% in the first quarter. BlackRock Inc. now owns 80,912 shares of the biotechnology company’s stock valued at $797,000 after acquiring an additional 52,114 shares during the period. Northern Trust Corp lifted its holdings in Eiger Biopharmaceuticals by 169.7% in the first quarter. Northern Trust Corp now owns 29,376 shares of the biotechnology company’s stock valued at $289,000 after acquiring an additional 18,483 shares during the period. Finally, Wedbush Securities Inc. bought a new position in Eiger Biopharmaceuticals in the first quarter valued at about $191,000. 65.92% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider Joanne Quan sold 4,000 shares of the stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $10.00, for a total transaction of $40,000.00. Following the transaction, the insider now owns 4,000 shares in the company, valued at approximately $40,000. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 7.90% of the company’s stock.



A number of research firms have weighed in on EIGR. Piper Jaffray Companies reissued an “overweight” rating and issued a $24.00 target price on shares of Eiger Biopharmaceuticals in a report on Wednesday, May 30th. B. Riley began coverage on Eiger Biopharmaceuticals in a report on Wednesday, May 9th. They issued a “buy” rating and a $24.00 target price on the stock. Zacks Investment Research downgraded Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 22nd. Oppenheimer set a $26.00 price objective on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 11th. Finally, ValuEngine raised Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 17th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Eiger Biopharmaceuticals has an average rating of “Buy” and an average target price of $28.50.

NASDAQ EIGR opened at $14.20 on Wednesday. Eiger Biopharmaceuticals Inc. has a 52 week low of $6.50 and a 52 week high of $18.00. The stock has a market capitalization of $151.78 million, a PE ratio of -2.92 and a beta of 1.81. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.51 and a current ratio of 4.51.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings results on Friday, May 11th. The biotechnology company reported ($0.84) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.96) by $0.12. equities analysts predict that Eiger Biopharmaceuticals Inc. will post -3.06 EPS for the current fiscal year.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Want to see what other hedge funds are holding EIGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR).

Institutional Ownership by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply